Inventor
Duane A. Burnett
Inventor
Bernardsville, NJ, US
Overview
Patents· 66 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Dprimary
C07DHeterocyclic compounds33%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
A61KPreparations for medical, dental or toiletry purposes14%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests5%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms3%
G01NInvestigating or analysing materials by determining their chemical or physical properties3%
Y02PClimate change mitigation technologies in the production or processing of goods3%
A61BDiagnosis2%
C07CAcyclic or carbocyclic compounds2%
C04BLime, magnesia1%
PatentTitleYear
10,959,879Methods and apparatus for cryogenic treatment of a body cavity or lumen202110,952,659Sensing Foley catheter202110,932,674Devices and methods for monitoring physiologic parameters202110,428,062Geminal substituted aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors201910,370,370Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors201910,183,938Geminal substituted quinuclidine amide compounds as agonists of a-7 nicotonic acetylcholine receptors20199,802,927'Oxadiazine compounds and methods of use thereof'20179,771,378'Fused morpholinopyrimidines and methods of use thereof'20179,499,502'5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions, and their use'20169,453,034'C2-azaspiro iminothiazine dioxides as BACE inhibitors, compositions, and their use'20169,365,589'C5, C6 oxacyclic-fused thiazine dioxide compounds as BACE inhibitors, compositions, and their use'20169,226,927'Gamma secretase inhibitors'20169,181,236'2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use'20158,987,195'HCV NS3 protease inhibitors'20158,933,116'Gamma secretase inhibitors'20158,907,086'Fused bicyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors'20148,809,318'Gamma secretase modulators'20148,691,832'Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors'20148,664,411'Tetrahydropyranochromene gamma secretase inhibitors'20148,618,123'Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors'20138,569,521'Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors'20138,450,343'Gamma secretase modulators'20138,067,621'Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors'20117,989,464'mGluR1 antagonists as therapeutic agents'2011RE042461'Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents'20117,902,157'Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism'20117,884,080'Azetidinone derivatives and methods of use thereof'20117,767,815'Fused tricyclic mGluR1 antagonists as therapeutic agents'20107,741,289'Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof'20107,732,413'Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof'20107,723,020'Use of azetidinone compounds'20107,687,501'Pyridothienopyridazinone derivatives as mGluR1 antagonists'20107,598,259'mGluR1 antagonists as therapeutic agents'20097,511,146'2-substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders'20097,504,391'Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders'20097,498,441'Biaryltetrahydroisoquinoline piperidines as selective MCH receptor antagonists for the treatment of obesity and related disorders'20097,485,648'mGluR1 antagonists as therapeutic agents'20097,482,360'Fused tetracyclic mGluR1 antagonists as therapeutic agents'20097,459,442'Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof'20087,423,149'Substituted n-aryl amidines as selective D1 dopamine receptor antagonists for the treatment of obesity and CNS disorders'20087,378,518'Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof'20087,368,563'Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof'20087,368,562'Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof'20087,235,543'Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof'20077,214,691'2-substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders'20077,211,574'Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders'20077,208,486'Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof'20077,192,944'Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof'20077,144,696'Use of azetidinone compounds'20067,109,207'Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity'20067,030,113'Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders'20066,933,107'Use of azetidinone compounds'20056,903,123'Azetidinyl diamines useful as ligands of the nociceptin receptor ORL-1'20056,664,273'Piperidine based MCH antagonists for treatment of obesity and CNS disorders'20036,632,933'Use of azetidinone compounds'20036,593,078'Use of azetidinone compounds'2003RE037721'Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents'20025,846,966'Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors'19985,767,115'Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents'19985,744,467'Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents'19985,698,548'Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents'19975,688,787'Substituted .beta.-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof'19975,656,624'4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents'19975,633,246'Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents'19975,631,365'Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents'19975,624,920'Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents'1997Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1997–2011Patents assigned to SCHERING CORP (42)· patent assignee history
1997–2002Based in Fanwood, NJ, US· patent location history
2003–2016Based in Bernardsville, NJ, US· patent location history
2011–2016Patents assigned to BURNETT DUANE A (11)· patent assignee history
2011–2016Patents assigned to WU WEN-LIAN (9)· patent assignee history
2011–2016Patents assigned to BENNETT CHAD E (6)· patent assignee history
2013–2016Patents assigned to MERCK SHARP & DOHME (13)· patent assignee history
2015–2019Based in Wayland, MA, US· patent location history
2021Based in San Francisco, CA, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| SCHERING CORP | 42 | 1997–2011 |
| MERCK SHARP & DOHME | 13 | 2013–2016 |
| BURNETT DUANE Aself | 11 | 2011–2016 |
| WU WEN-LIAN | 9 | 2011–2016 |
| BENNETT CHAD E | 6 | 2011–2016 |
Locations
| Location | Patents | Span |
|---|---|---|
| Bernardsville, New Jersey, US | 43 | 2003–2016 |
| Wayland, Massachusetts, US | 10 | 2015–2019 |
| Fanwood, New Jersey, US | 10 | 1997–2002 |
| San Francisco, California, US | 3 | 2021 |